Spruce Biosciences, Inc.
TA-ERT
MPS IIIB
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews TA-ERT for MPS IIIB around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 12h ago
“The FDA confirmed that the integrated study data from interventional clinical studies of TA-ERT and the available natural history data could potentially serve as an adequate and well-controlled study for purposes of the FDA’s review of the ”